近期，國家應急防控藥物工程技術研究中心等研究人員發表《中東呼吸綜合征的臨床治療和小分子治療藥物研究進展》研究，該文章發表於2015年3期的《國際藥學研究雜誌》上。

        中東呼吸綜合征(MERS)是由新型冠狀病毒MERS-CoV感染引起的傳染病，2012年在沙特被首次發現，疫情主要集中在中東地區，在歐洲、非洲、北美洲和亞洲也有少量病例報告，近期韓國連續報告數十病例，並且1例經香港輸入中國大陸地區。目前，臨床上尚無針對MERS-CoV的特異性抗病毒藥物和治療方法，主要是對症治療，在防止並發症的同時實施有效的呼吸、循環支持和腎功能保護。本文對文獻報道的潛在臨床治療方法，抗MERS-CoV的潛在藥物靶點和小分子治療藥物的研究進展進行綜述。

Abstract：

        Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the newly identified MERS-CoV, which was first discovered in Saudi Arabia in 2012. Although most cases of MERS have occurred in Middle East, cases also have been reported in Europe, the USA and Asia in people who travelled from the Middle East or their contacts. The most recent outbreak was in South Korea with over dozens of cases, wherein, one case imported into mainland China via Hong Kong. No specific drug treatment exists for MERS now. Supportive treatment, aiming to prevent complications, supporting the function of respiratory, circulatory and renal, was the mainstay of management. In this paper, the reported clinical treatment, the research progress of potential targets and small molecule drugs for anti MERS-CoV were reviewed.